

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 January 2009 (15.01.2009)

PCT

(10) International Publication Number
WO 2009/007441 A3

(51) International Patent Classification:

A61K 31/505 (2006.01) A61P 31/18 (2006.01)
C07D 239/48 (2006.01)

(21) International Application Number:

PCT/EP2008/059054

(22) International Filing Date: 11 July 2008 (11.07.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

07112392.1 12 July 2007 (12.07.2007) EP

(71) Applicant (for all designated States except US): **Tibotec Pharmaceuticals Ltd.** [IE/IE]; Eastgate Village, Eastgate, Little Island, Co Cork (IE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **STOKBROEKX, Sigrid, Carl, Maria** [BE/BE]; Kempenlaan 20, B-2340 Beerse (BE). **LEYS, Carina** [BE/BE]; Mattenvlechters 4, B-3940 Stabroek (BE). **THEUNISSEN, Elisabeth Maria Hélène Egide Ghislaine** [BE/BE]; Aarschotsesteenweg 568, B-3012 Wilsele (BE). **BAERT, Lieven Elvire Collette** [BE/BE]; Jozef Van Wallegemstraat 11, B-8200 Brugge 2 (BE).

(74) Agent: **WANTE, Dirk**; Tibotec-Virco Comm. VA, J & J Patent Law Department, Generaal De Wittelaan L 11B 3, B-2800 Mechelen (BE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
30 April 2009

(54) Title: CRYSTALLINE FORM OF (E) 4-[[4-[[4-(2-CYANOETHENYL)-2,6-DIMETHYLPHENYL]AMINO]-2-PYRIMIDINYL]AMINO]BENZONITRILE

(57) Abstract: This invention concerns polymorph I of TMC278, its use and preparation. It further concerns pharmaceutical formulations comprising this polymorph.



WO 2009/007441 A3

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2008/059054

A. CLASSIFICATION OF SUBJECT MATTER

INV. A61K31/505 C07D239/48 A61P31/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 03/016306 A (JANSSEN PHARMACEUTICA NV [BE]; GUILLEMONT JEROME EMILE GEORGE [FR]; PA) 27 February 2003 (2003-02-27) cited in the application Page 49, line 33 - page 50, line 5. Page 67, Example B1. Page 68, Example B1B. page 1, line 24 - line 30 -----	1-10
X	WO 2004/016581 A (JANSSEN PHARMACEUTICA NV [BE]; SCHILS DIDIER PHILIPPE ROBERT [BE]; WIL) 26 February 2004 (2004-02-26) Page 23, Example B. ----- -/--	1-4

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* & * document member of the same patent family

Date of the actual completion of the international search

10 February 2009

Date of mailing of the international search report

24/02/2009

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Von Daacke, Axel

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2008/059054

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JANSSEN, PAUL A. J. ET AL: "In Search of a Novel Anti-HIV Drug: Multidisciplinary Coordination in the Discovery of 4-[[4-[[4-[(1E)-2-Cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, Rilpivirine)" JOURNAL OF MEDICINAL CHEMISTRY, 48(6), 1901-1909 CODEN: JMCMAR; ISSN: 0022-2623, 2005, XP002460263 Page 1907: "Requirement 4". -----	1-4
X	GUILLEMONT, JEROME ET AL: "Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1" JOURNAL OF MEDICINAL CHEMISTRY, 48(6), 2072-2079 CODEN: JMCMAR; ISSN: 0022-2623, 2005, XP002460264 compound 6A -----	1-4
A	WO 2006/024668 A (JANSSEN PHARMACEUTICA NV [BE]; TIBOTEC PHARM LTD [IE]; STEVENS PAUL TH) 9 March 2006 (2006-03-09) the whole document -----	1-5

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2008/059054

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03016306	A	27-02-2003	AP 1610 A	30-06-2006
			BR 0211909 A	24-08-2004
			CA 2452217 A1	27-02-2003
			CN 1541215 A	27-10-2004
			EP 1419152 A1	19-05-2004
			HR 20040096 A2	30-06-2004
			HU 0401346 A2	28-12-2004
			JP 2005507380 T	17-03-2005
			KR 20070101409 A	16-10-2007
			MX PA04001401 A	27-05-2004
			NO 20040633 A	12-03-2004
			NO 20083770 B	12-03-2004
			NZ 530951 A	28-10-2005
			OA 12652 A	15-06-2006
			PA 8552901 A1	28-02-2003
			US 2006252764 A1	09-11-2006
			US 2004198739 A1	07-10-2004
WO 2004016581	A	26-02-2004	AU 2003266413 A1	03-03-2004
			BR 0313545 A	12-07-2005
			CA 2493794 A1	26-02-2004
			CN 1681774 A	12-10-2005
			HR 20050104 A2	31-03-2006
			IS 7621 A	29-12-2004
			JP 2005537303 T	08-12-2005
			KR 20050040906 A	03-05-2005
			MX PA05001541 A	19-04-2005
			NZ 538611 A	30-03-2007
			US 2008167464 A1	10-07-2008
			US 2006167253 A1	27-07-2006
			US 2007191407 A1	16-08-2007
WO 2006024668	A	09-03-2006	AU 2005279158 A1	09-03-2006
			CA 2577288 A1	09-03-2006
			KR 20070074555 A	12-07-2007